Analyst Ratings for Ligand Pharma (LGND)
LGND Rating Summary
LGND Price Target Summary
- Highest: $157.00 (H.C. Wainwright)
- Lowest: $125.00 (Barclays)
- Average: $142.14
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$142.14 (+35.4%)
* Over Last 12-Mos
Rating Score: 6.7 / 10
Percentile Rank: 69%
Avg. $ Target:
$142.14 (+35.4%)
* Over Last 12-Mos
Rating Score: 6.7 / 10
Percentile Rank: 69%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/10/2025 | Stifel | Annabel Samimy | New Coverage | Buy (N/A) |
143.00 (N/A) |
96.67 (104.97) |
8.59% | Details |
| 10/1/2024 | Oppenheimer » Updated 2/28/2025 |
Trevor Allred | New Coverage | Outperform (N/A) |
142.00 (151.00) |
101.35 (104.97) |
3.57% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
